etherna is a platform driven RNA-LNP technology company with decades of scientific, formulation, and process expertise. We partner with pharma and biotech organizations developing nucleic acid–based therapeutics, supporting teams from early discovery through late‑stage development.
Our proprietary LNP platforms are engineered to support the development of nucleic acid–based therapeutics across multiple routes of administration, including IV, intratumoral, and intramuscular delivery. Each platform is optimized for targeted biodistribution and efficient payload delivery, enabling partners to advance RNA and other nucleic acid modalities with greater precision.
Our RNA chemistry platform enables advanced sequence engineering to optimize translation efficiency, molecular stability, and immunogenicity. Using proprietary design tools and deep expertise in nucleic acid chemistry, we develop constructs tailored for immune‑silent, immune‑stimulatory, or tissue‑specific expression, supporting partners in designing high‑quality RNA for diverse nucleic acid therapeutic applications.
Our technology partnering model provides access to Etherna’s proprietary RNA chemistry and LNP delivery platforms, enabling the design, optimization, and advancement of nucleic acid–based therapeutics. Through collaborative co‑development, we work with partners to address sequence design, formulation, biodistribution, and process challenges supporting programs from early discovery through clinical development.
We advance a focused pipeline of nucleic acid–based therapeutic programs built on our proprietary RNA and LNP platforms. Our portfolio includes an IV‑administered oncology candidate (clinically ready), an intratumoral platform incorporating a proprietary immune‑activating mix, and an ex vivo dendritic‑cell activation approach supported by Phase 2 clinical data, offering opportunities for co‑development and strategic collaboration.
With more than 30 years of RNA manufacturing experience and over five years of GMP RNA production in our cGMP‑accredited facility in Niel, Belgium, we provide high‑quality RNA materials to support research, preclinical, and clinical development. Our manufacturing capabilities are tightly integrated with our technology platforms, enabling seamless progression from design to production.